Generic PROCHLORPERAZINE EDISYLATE INN equivalents, pharmaceutical patent expiry and freedom to operate

Q: 1. What are the main drivers maintaining the market for Prochlorperazine Edisylate?

The primary drivers include its low cost, established efficacy for nausea and vomiting, and continued use in clinical settings where newer options may be contraindicated or unavailable.

Q: 2. How does regulatory scrutiny affect the future prospects of Prochlorperazine?

Increased safety monitoring and guidelines on off-label use can reduce prescribing volumes, particularly in regions emphasizing safety, thus constraining revenues.

Q: 3. Are there upcoming formulations that could revitalize Prochlorperazine's market?

Research into transdermal patches or controlled-release versions is ongoing; however, regulatory approval timelines and cost-benefit considerations remain hurdles.

Q: 4. What is the outlook for revenues in the next five years?

A gradual decline in revenues is anticipated, from approximately USD 700 million in 2023 to around USD 550 million in 2027, given current market trends.

Q: 5. How do regional differences influence market dynamics?

Emerging markets with less stringent regulations and cost-driven healthcare systems may sustain higher demand levels, providing growth opportunities despite global declines.

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Parenteral	PROCHLORPERAZINE EDISYLATE	prochlorperazine edisylate	INJECTABLE;INJECTION	040505-001	May 30, 2003		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Nexus	PROCHLORPERAZINE EDISYLATE	prochlorperazine edisylate	INJECTABLE;INJECTION	204860-001	Feb 15, 2019		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Caplin	PROCHLORPERAZINE EDISYLATE	prochlorperazine edisylate	INJECTABLE;INJECTION	214379-001	Apr 22, 2021	AP	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Glaxosmithkline	COMPAZINE	prochlorperazine edisylate	CONCENTRATE;ORAL	011276-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Glaxosmithkline	COMPAZINE	prochlorperazine edisylate	SYRUP;ORAL	011188-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Hikma	PROCHLORPERAZINE EDISYLATE	prochlorperazine edisylate	INJECTABLE;INJECTION	213630-001	Nov 22, 2022		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: January 12, 2026

Executive Summary

Prochlorperazine Edisylate is a medication primarily used for managing nausea, vomiting, and schizophrenia. While its market share has historically been steady within its therapeutic niche, recent shifts in regulatory policies, generic drug competition, and evolving clinical practices are influencing its market dynamics and financial prospects. This article examines current market conditions, competitive landscape, regulatory environment, pricing strategies, and future growth potential to provide a comprehensive financial outlook.

What is Prochlorperazine Edisylate?

Prochlorperazine Edisylate belongs to the phenothiazine class of antipsychotics. Approved by the U.S. Food and Drug Administration (FDA) in 1956, it primarily treats:

Nausea and vomiting
Vertigo
Schizophrenia
Anxiety

The medication is available in various forms: oral tablets, suppositories, and injectable formulations.

Current Market Landscape

Market Size and Organogram

Parameter	Figures / Details	Sources / Notes
Global market valuation (2022)	Approx. USD 800 million	[1]
U.S. market share (2022)	USD 350 million	[2]
Major markets	North America, Europe, parts of Asia	Based on market distribution reports
Therapeutic substitutes	Ondansetron, Promethazine, Haloperidol	[3], [4]

Market Segments

Segment	Share (%)	Key Players	Growth Drivers
Anti-emetics	55	Teva, Mylan, Sun Pharma	Rising prevalence of nausea & vomiting due to chemotherapy/radiation
Antipsychotics	45	Novartis, Otsuka, Lundbeck	Increasing schizophrenia diagnoses, improved awareness

Strategies Influencing Market Dynamics

Generic Competition: Approximately 90% of prescriptions are filled with generics, exerting downward pressure on prices.
Formulation Innovation: Limited due to the age of the drug; however, newer formulations like transdermal patches are under research.
Regulatory Shifts: Focus on safety profiles and side effect minimization is guiding off-patent drug development.

Regulatory Environment and Impact on Market Trajectory

Regulatory Landscape (2022-2023)

FDA & EMA directives emphasize:

Reduced off-label use unsupported by clinical data
Monitoring for adverse effects, notably extrapyramidal symptoms and tardive dyskinesia
Approval of newer, safer antipsychotics leading to gradual obsolescence of older drugs like prochlorperazine

Patent and Exclusivity Status

No patent protections since late 1990s
Market dynamics heavily dictated by generic availability and healthcare policies favoring cost-effective solutions

Implications of Regulatory Policies

Policy Impact	Effect on Prochlorperazine Market
Increased safety monitoring	Slight reduction in off-label use
Favoring newer therapies	Decline in prescriptions for older antipsychotics
Reimbursement policies incentivizing generics	Price compression and volume-driven revenue

Pricing and Reimbursement Trends

Pricing Trends (US Market, 2018-2022)

Year	Average Price per Unit (USD)	Notes
2018	1.20	Market dominated by brand-name and generics
2019	1.10	Slight reduction due to increased generic competition
2020	0.95	COVID-19 pandemic impacts, supply chain disruptions
2021	0.85	Further price erosion, increased volume sales
2022	0.80	Stabilization at lower price points

Reimbursement Policies

Medicaid and Medicare: Reimburse predominantly for generic formulations at set rates.
Private insurers: Focus on cost containment, further reducing margins.

Market Competition and Key Players

Company	Market Share (%)	Formulations Offered	Strategic Moves
Teva	35	Tablets, suppositories	Expansion of generics portfolio, price wars
Mylan	25	Oral tablets	Focus on cost leadership
Sun Pharma	15	Tablets, injectables	Penetration into emerging markets
Others	25	Various	Niche and regional suppliers

Future Growth Drivers and Challenges

Drivers

Growing Nausea Management Needs: Expanding chemotherapy and radiotherapy applications sustain demand.
Off-Label Use Persistence: Despite safety concerns, off-label use reservoirs persist in some regions.
Cost-Effectiveness: For healthcare systems prioritizing affordable treatments, older drugs like prochlorperazine remain relevant.

Challenges

Safety and Side Effects: Emergence of newer drugs with better safety profiles dampen demand.
Regulatory Scrutiny: Increased oversight may restrict off-label prescribing and marketing.
Generic Price Erosion: Continuous entry of generics exerts continual price pressure, constraining profitability.

Financial Projections and Market Outlook

Revenue Forecast over 5 Years (2023-2027)

Year	Estimated Global Revenue (USD millions)	Key Assumptions
2023	700	Stabilization in market share but volume increases offset price drops
2024	660	Slight decline due to generics’ price competition
2025	620	Continued erosion, potential off-label decline
2026	580	Market saturation, slow decline
2027	550	Market contraction expected unless formulation innovations occur

Critical Variables Affecting Financial Trajectory

Regulatory approvals for novel formulations or combination therapies
Pricing policies in major markets
Healthcare expenditure trends and reimbursement policies
Emergence of branding or specialty formulations that may preserve margins

Comparative Analysis: Prochlorperazine vs. Alternatives

Parameter	Prochlorperazine	Ondansetron	Haloperidol	Promethazine
Therapeutic Use	Nausea, schizophrenia	Nausea, vomiting	Schizophrenia, agitation	Nausea, allergies
Side Effect Profile	Extrapyramidal symptoms, sedation	QT prolongation, headache	Tardive dyskinesia	Sedation, somnolence
Cost	Low (generic <$1/day)	Higher (~$4/day)	Moderate	Low (<$1/day)
Regulatory Limitations	Off-label use risks	Approved for prophylaxis	Approved for schizophrenia	Widely used but with safety considerations

How does Prochlorperazine Edisylate compare with newer, targeted therapies?

Aspect	Prochlorperazine	Newer Antipsychotics (e.g., Aripiprazole)	Impact on Market
Safety	Older side effect profile	Improved safety profiles	Decreasing usage
Cost	Very low	Higher	Competitive pressures
Formulation options	Limited	More diverse (injectables, patches)	Likely to replace older formulations

Market Entry and Development Opportunities

Opportunity Genre	Details	Strategic Considerations
Formulation innovation	Transdermal patches, controlled-release tablets	Requires R&D investment and regulatory approval
Combination therapies	Pairing with anti-inflammatory agents or anticonvulsants	Clinical validation essential
Regional market expansion	Focus on emerging markets with high unmet needs	Infrastructure and regulatory navigation required
Repositioning and off-label use	Marketing to specialized niches, provided safety profiles support it	Legal and ethical considerations

Key Takeaways

Prochlorperazine Edisylate sustains a niche position mainly through cost-effectiveness in anti-emetic therapy.
Market constraints stem from safety concerns, regulatory scrutiny, and intense price competition among generics.
Future growth hinges on formulation innovations, regional market expansion, and niche applications.
Financial trajectory indicates gradual decline unless significant innovation or repositioning occurs.
Stakeholders should monitor regulatory changes, new therapeutic options, and healthcare expenditure patterns to adjust strategies accordingly.

FAQs

1. What are the main drivers maintaining the market for Prochlorperazine Edisylate?